OTCPK:OSSF.F

Stock Analysis Report

Executive Summary

Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific.

Snowflake

Fundamentals

Proven track record with mediocre balance sheet.


Similar Companies

Share Price & News

How has Össur hf's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.4%

OSSF.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

74.1%

OSSF.F

9.9%

US Medical Equipment

0.6%

US Market

OSSF.F outperformed the Medical Equipment industry which returned 9.5% over the past year.

OSSF.F outperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

OSSF.FIndustryMarket
7 Day11.4%1.1%-0.6%
30 Day18.9%0.6%2.2%
90 Dayn/a2.9%1.1%
1 Year74.1%74.1%10.8%9.9%2.9%0.6%
3 Year103.1%103.1%70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Össur hf's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Össur hf undervalued based on future cash flows and its price relative to the stock market?

36.03x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Össur hf's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Össur hf's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Össur hf is good value based on earnings compared to the US Medical Equipment industry average.

Össur hf is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Össur hf is poor value based on expected growth next year.


Price Based on Value of Assets

Össur hf is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Össur hf expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

12.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Össur hf's revenue is expected to grow by 6.8% yearly, however this is not considered high growth (20% yearly).

Össur hf's earnings are expected to grow by 12.3% yearly, however this is not considered high growth (20% yearly).

Össur hf's revenue growth is positive but not above the United States of America market average.

Össur hf's earnings growth is positive but not above the United States of America market average.

Össur hf's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Össur hf is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Össur hf performed over the past 5 years?

7.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Össur hf's year on year earnings growth rate has been positive over the past 5 years.

Össur hf's 1-year earnings growth exceeds its 5-year average (32.5% vs 7.6%)

Össur hf's earnings growth has exceeded the US Medical Equipment industry average in the past year (32.5% vs 28.2%).


Return on Equity

Össur hf has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Össur hf used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Össur hf's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Össur hf's financial position?


Financial Position Analysis

Össur hf is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Össur hf's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Össur hf's level of debt (40.8%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (30.1% vs 40.8% today).

Debt is well covered by operating cash flow (37.4%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 17.6x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Next Steps

Dividend

What is Össur hf's current dividend yield, its reliability and sustainability?

0.39%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Össur hf's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

Össur hf's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Össur hf is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Össur hf is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Össur hf's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Össur hf's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Össur hf's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Jón Sigurdsson (63yo)

23.7yrs

Tenure

US$2,062,000

Compensation

Mr. Jón Sigurdsson has been the Chief Executive Officer and President of Gibaud SAS since 1996. Mr. Sigurdsson has been Senior Vice President of Procurement at Promens Canada Inc. and Promens hf. since Jul ...


CEO Compensation Analysis

Jón's remuneration is lower than average for companies of similar size in United States of America.

Jón's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.0yrs

Average Tenure

50yo

Average Age

The tenure for the Össur hf management team is about average.


Board Age and Tenure

10.7yrs

Average Tenure

62yo

Average Age

The average tenure for the Össur hf board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Jón Sigurdsson (63yo)

    CEO & President

    • Tenure: 23.7yrs
    • Compensation: US$2.06m
  • Ossur Kristinsson (76yo)

    • Tenure: 0yrs
    • Compensation: US$25.00k
  • Egill Jónsson (62yo)

    Executive Vice President of Manufacturing & Operations

    • Tenure: 0yrs
    • Compensation: US$444.00k
  • Ólafur Gylfason (50yo)

    Executive Vice President of Sales & Marketing

    • Tenure: 3.6yrs
    • Compensation: US$600.00k
  • Sigurborg Arnarsdottir

    Compliance Officer

    • Tenure: 17.7yrs
  • Sveinn Sölvason (41yo)

    Chief Financial Officer

    • Tenure: 6.3yrs
    • Compensation: US$221.00k
  • Margrét Friðriksdóttir (41yo)

    Executive Vice President of Human Resources & Corporate Strategy

    • Tenure: 0yrs
    • Compensation: US$242.00k
  • Kim de Roy (42yo)

    Executive Vice President of Research & Development

    • Tenure: 1.8yrs
  • Gudjon Karason (50yo)

    Executive Vice President of Clinics

    • Tenure: 1.8yrs
  • David Hreidarsson

    Investor Relations Manager

    • Tenure: 0yrs

Board Members

  • Niels Jacobsen (62yo)

    Chairman of the Board

    • Tenure: 13.7yrs
    • Compensation: US$94.00k
  • Kristján Ragnarsson (76yo)

    Vice Chairman

    • Tenure: 7.5yrs
    • Compensation: US$56.00k
  • Svafa Grönfeldt (54yo)

    Director

    • Tenure: 11.7yrs
    • Compensation: US$38.00k
  • Guðbjörg Eggertsdóttir (68yo)

    Director

    • Tenure: 6.5yrs
    • Compensation: US$38.00k
  • Arne Nielsen (51yo)

    Director

    • Tenure: 10.7yrs
    • Compensation: US$38.00k

Company Information

Össur hf.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Össur hf.
  • Ticker: OSSF.F
  • Exchange: OTCPK
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ø21.237b
  • Listing Market Cap: ø3.129b
  • Shares outstanding: 423.04m
  • Website: https://www.ossur.com

Number of Employees


Location

  • Össur hf.
  • Grjothals 1 - 5
  • Reykjavik
  • 110
  • Iceland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
0FIWLSE (London Stock Exchange)YesCommon StockGBDKKOct 1999
OSSRCPSE (OMX Nordic Exchange Copenhagen)YesCommon StockDKDKKOct 1999
OSSRCBATS-CHIXE (BATS 'Chi-X Europe')YesCommon StockGBDKKOct 1999
OSSF.FOTCPK (Pink Sheets LLC)YesCommon StockUSUSDOct 1999
OSSU.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDDec 2011

Biography

Össur hf., together with its subsidiaries, develops, produces, and sells non-invasive orthopedic products in Europe, the Middle-East, Africa, the Americas, and the Asia-Pacific. The company’s prosthetics p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:17
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.